Open AccessTherapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments
Author(s) -
Scott D. Lee,
Raina Shivashankar,
Daniel Quirk,
Haiying Zhang,
Jean Baptiste Telliez,
John M. Andrews,
Amy Marren,
Arnab Mukherjee,
Edward V. Loftus
Publication year - 2020
Publication title -
journal of clinical gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.141
H-Index - 112
eISSN - 1539-2031
pISSN - 0192-0790
DOI - 10.1097/mcg.0000000000001396
Subject(s) - medicine , tofacitinib , therapeutic drug monitoring , inflammatory bowel disease , ulcerative colitis , thiopurine methyltransferase , vedolizumab , infliximab , adalimumab , methotrexate , natalizumab , pharmacology , dosing , ustekinumab , drug , immunology , disease , rheumatoid arthritis
This article reviews therapeutic drug monitoring (TDM) use for current inflammatory bowel disease (IBD) treatments. IBD comprises Crohn's disease and ulcerative colitis-chronic gastrointestinal inflammatory disorders. Treatment options for moderate to severe IBD include thiopurines; methotrexate; biologic agents targeting tumor necrosis factor, α4β7 integrin or interleukins 12 and 23; and Janus kinase inhibitors. TDM is recommended to guide treatment decisions for some of these agents. Published literature concerning TDM for IBD treatments was reviewed. S.D.L., R.S., and E.V.L. drew on their clinical experiences. Polymorphisms resulting in altered enzymatic activity inactivating thiopurine metabolites can lead to myelotoxicity and hepatotoxicity. Increased elimination of biologic agents can result from immunogenicity or higher disease activity, leading to low drug concentration and consequent nonresponse or loss of response. TDM may aid treatment and dose decisions for individual patients, based on monitoring metabolite levels for thiopurines, or serum drug trough concentration and antidrug antibody levels for biologic agents. Challenges remain around TDM implementation in IBD, including the lack of uniform assay methods and guidance for interpreting results. The Janus kinase inhibitor tofacitinib is not impacted by enzyme polymorphisms or disease activity, and is not expected to stimulate the formation of neutralizing antidrug antibodies. TDM is associated with implementation challenges, despite the recommendation of its use for guiding many IBD treatments. Newer small molecules with less susceptibility to patient variability factors may fulfill the unmet need of treatment options that do not require TDM, although further study is required to confirm this.